Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Tim Heiland"'
Autor:
Marc-Eric Halatsch, Annika Dwucet, Carl Julius Schmidt, Julius Mühlnickel, Tim Heiland, Katharina Zeiler, Markus D. Siegelin, Richard Eric Kast, Georg Karpel-Massler
Publikováno v:
Pharmaceuticals, Vol 14, Iss 12, p 1241 (2021)
Background: Glioblastoma represents the most common primary brain tumor in adults. Despite technological advances, patients with this disease typically die within 1–2 years after diagnosis. In the search for novel therapeutics, drug repurposing has
Externí odkaz:
https://doaj.org/article/c4891d57756d4b0b973fc1555f50a04e
Autor:
Richard E. Kast, Alex P. Michael, Iacopo Sardi, Terry C. Burns, Tim Heiland, Georg Karpel-Massler, Francois G. Kamar, Marc-Eric Halatsch
Publikováno v:
Brain Sciences, Vol 10, Iss 1, p 51 (2020)
Prognosis for diffuse intrinsic pontine glioma (DIPG) and generally for diffuse midline gliomas (DMG) has only marginally improved over the last ~40 years despite dozens of chemotherapy and other therapeutic trials. The prognosis remains invariably f
Externí odkaz:
https://doaj.org/article/89f2a527688f4ef69437527885f1a9ca
Autor:
Richard E Kast, Quentin A Hill, Didier Wion, Håkan Mellstedt, Daniele Focosi, Georg Karpel-Massler, Tim Heiland, Marc-Eric Halatsch
Publikováno v:
Tumor Biology, Vol 39 (2017)
Increased ratio of circulating neutrophils to lymphocytes is a common finding in glioblastoma and other cancers. Data reviewed establish that any damage to brain tissue tends to cause an increase in G-CSF and/or GM-CSF (G(M)-CSF) synthesized by the b
Externí odkaz:
https://doaj.org/article/1f37184334fb4ccbbd7dd8ef9dd87e85
Autor:
Sebastian Weckbach, Mario Perl, Tim Heiland, Sonja Braumüller, Philip F. Stahel, Michael A. Flierl, Anita Ignatius, Florian Gebhard, Markus Huber-Lang
Publikováno v:
Mediators of Inflammation, Vol 2012 (2012)
Background. The molecular mechanisms of the immune response after polytrauma are highly complex and far from fully understood. In this paper, we characterize a new standardized polytrauma model in rats based on the early molecular inflammatory and ap
Externí odkaz:
https://doaj.org/article/32515946508a4c038e539ee54e8fb48e
Autor:
Carl Schmidt, Annika Dwucet, Richard E. Kast, Julius Mühlnickel, Georg Karpel-Massler, Marc-Eric Halatsch, Tim Heiland, Katharina Zeiler, Markus D. Siegelin
Publikováno v:
Pharmaceuticals; Volume 14; Issue 12; Pages: 1241
Pharmaceuticals
Pharmaceuticals, Vol 14, Iss 1241, p 1241 (2021)
Pharmaceuticals
Pharmaceuticals, Vol 14, Iss 1241, p 1241 (2021)
Background: Glioblastoma represents the most common primary brain tumor in adults. Despite technological advances, patients with this disease typically die within 1–2 years after diagnosis. In the search for novel therapeutics, drug repurposing has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::017595624cf135f1d61d9d5c1946c436
Autor:
Anke Hallmen, Angelika Scheuerle, Gauthier Bouche, Birgit Schmelzle, Carl Schmidt, Benjamin Mayer, Katharina Zeiler, Regine Mayer-Steinacker, Richard E. Kast, Mike-Andrew Westhoff, Lars Bullinger, Patricia Panther, Oliver Zolk, Ludwig Maier, Georg Karpel-Massler, Ziad Elshaer, Marc-Eric Halatsch, Annika Dwucet, Kristine Beckers, Tim Heiland, Bernd Schmitz, Markus D. Siegelin
Publikováno v:
Neuro-oncology Advances
Background The dismal prognosis of glioblastoma (GBM) may be related to the ability of GBM cells to develop mechanisms of treatment resistance. We designed a protocol called Coordinated Undermining of Survival Paths combining 9 repurposed non-oncolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3b9b1ea9dcb850a01dc4e3c68ffbcb8
https://pubmed.ncbi.nlm.nih.gov/34377985
https://pubmed.ncbi.nlm.nih.gov/34377985
Autor:
Tim Heiland, Christian Rainer Wirtz, Jenson Anthonymuthu, Maximilian Pruss, Mayas Bilal, Richard E. Kast, Marc-Eric Halatsch, Mike-Andrew Westhoff, Annika Dwucet, Felix Capanni, Nicolas Bader, Markus D. Siegelin, Carolin Golla, Georg Karpel-Massler
Publikováno v:
Cancers, Vol 13, Iss 4123, p 4123 (2021)
Cancers
Volume 13
Issue 16
Cancers
Volume 13
Issue 16
The purpose of this study was to assess in vitro whether the biological effects of 5-aminolevulinic acid (5-ALA)-based photodynamic therapy are enhanced by inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL in different glioblast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2fdd2457cab53b25ce87e0084a8e526
https://www.mdpi.com/2072-6694/13/16/4123
https://www.mdpi.com/2072-6694/13/16/4123
Autor:
Michal Hlavac, Mike-Andrew Westhoff, Richard E. Kast, Tim Heiland, Klaus-Michael Debatin, Christian Rainer Wirtz, Annika Dwucet, Markus D. Siegelin, Marc-Eric Halatsch, Georg Karpel-Massler
Publikováno v:
Br J Pharmacol
Background and purpose Drug repurposing represents a promising approach to safely accelerate the clinical application of therapeutics with anti-cancer activity. In this study, we examined whether inhibition of the anti-apoptotic Bcl-2 family proteins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9ba9e75fd2de6c6ee725726c167e2b7
https://doi.org/10.1111/bph.14773
https://doi.org/10.1111/bph.14773
Autor:
Marc-Eric Halatsch, Bernd Schmitz, Lars Bullinger, Oliver Zolk, Annika Dwucet, Katharina Zeiler, Birgit Schmelzle, Markus D. Siegelin, Regine Mayer-Steinacker, Ludwig Maier, Gauthier Bouche, Mike-Andrew Westhoff, Patricia Panther, Anke Hallmen, Angelika Scheuerle, Richard E. Kast, Ziad Elshaer, Kristine Beckers, Tim Heiland, Benjamin Mayer, Carl Schmidt, Georg Karpel-Massler
Purpose: The dismal prognosis of glioblastoma (GBM) may be related to the ability of GBM cells to develop mechanisms of treatment resistance. We designed a protocol called Coordinated Undermining of Survival Paths combining 9 repurposed non-oncologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1842d22c73b044a1551d481a13ae9a7
https://doi.org/10.21203/rs.3.rs-162394/v1
https://doi.org/10.21203/rs.3.rs-162394/v1
Autor:
Georg Karpel-Massler, Benjamin Mayer, Anke Hallmen, Patricia Panther, Katharina Zeiler, Tim Heiland, Ziad Elshaer, Carl Schmidt, Markus D. Siegelin, Birgit Schmelzle, Regine Mayer-Steinacker, Lars Bullinger, Oliver Zolk, Annika Dwucet, Gauthier Bouche, Bernd Schmitz, Kristine Beckers, Ludwig Maier, Angelika Scheuerle, Marc-Eric Halatsch, Mike-Andrew Westhoff, Richard E. Kast
Publikováno v:
Neuro-Oncology. 23:vi59-vi59
CUSP9v3 is a new treatment regimen for glioblastoma. It consists of continuous daily use of 9 drugs repurposed from general medicine. Their primary non-oncology uses are given in parentheses: aprepitant (nausea), auranofin (rheumatoid arthritis), cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::676e4a52d26a432aa874febb49fb3739
https://doi.org/10.1093/neuonc/noab196.229
https://doi.org/10.1093/neuonc/noab196.229